id	sid	eid	entity	type
dpc-4838	2	1	2025;15(1):4838 1	CARDINAL
dpc-4838	2	2	secukinumab	PERSON
dpc-4838	2	3	italy	GPE
dpc-4838	2	4	federico pirro1,2	PERSON
dpc-4838	2	5	giacomo caldarola1,2	PERSON
dpc-4838	2	6	nicoletta bernardini3	GPE
dpc-4838	2	7	maria grazia celeste4	PERSON
dpc-4838	2	8	dattola5	PERSON
dpc-4838	2	9	eleonora de luca1,2	PERSON
dpc-4838	2	10	galluzzo6	PRODUCT
dpc-4838	2	11	domenico giordano7	PERSON
dpc-4838	2	12	izzi4	ORG
dpc-4838	2	13	marcelli6	PERSON
dpc-4838	2	14	roberto ravasio9	PERSON
dpc-4838	2	15	antonio giovanni richetta5	PERSON
dpc-4838	2	16	skroza3	PERSON
dpc-4838	2	17	talamonti6	PERSON
dpc-4838	2	18	arianna zangrilli6	PERSON
dpc-4838	2	19	bianchi6	PERSON
dpc-4838	2	20	giovanni pellacani5	PERSON
dpc-4838	2	21	persechino7	EVENT
dpc-4838	2	22	concetta potenza3	PERSON
dpc-4838	2	23	ketty peris1,2	PERSON
dpc-4838	2	24	clara de simone1,2 1	PERSON
dpc-4838	2	25	uoc di dermatologia	PERSON
dpc-4838	2	26	di scienze mediche e chirurgiche	ORG
dpc-4838	2	27	fondazione policlinico universitario a. gemelli irccs	ORG
dpc-4838	2	28	rome	GPE
dpc-4838	2	29	italy 2	ORG
dpc-4838	2	30	di medicina e chirurgia traslazionale	ORG
dpc-4838	2	31	università cattolica del sacro cuore	ORG
dpc-4838	2	32	rome	GPE
dpc-4838	2	33	italy 3	ORG
dpc-4838	2	34	sapienza university of rome	ORG
dpc-4838	2	35	italy 4	FAC
dpc-4838	2	36	rome	GPE
dpc-4838	2	37	italy 5	ORG
dpc-4838	2	38	sapienza university	ORG
dpc-4838	2	39	rome	GPE
dpc-4838	2	40	italy 6	ORG
dpc-4838	2	41	university of rome	ORG
dpc-4838	2	42	rome	GPE
dpc-4838	2	43	italy 7	ORG
dpc-4838	2	44	sapienza university of roma	ORG
dpc-4838	2	45	rome	GPE
dpc-4838	2	46	italy 8	GPE
dpc-4838	2	47	university of la sapienza	ORG
dpc-4838	2	48	rome	GPE
dpc-4838	2	49	italy 9 heor &rwe	ORG
dpc-4838	2	50	italy	GPE
dpc-4838	2	51	risankizumab	ORG
dpc-4838	2	52	secukinumab	PERSON
dpc-4838	2	53	caldarola	ORG
dpc-4838	3	1	risankizumab	PERSON
dpc-4838	3	2	secukinumab	PERSON
dpc-4838	3	3	italy	GPE
dpc-4838	5	1	2025;15(1):4838	CARDINAL
dpc-4838	5	2	august 28, 2024	DATE
dpc-4838	6	1	january 2025	DATE
dpc-4838	6	2	2024	CARDINAL
dpc-4838	7	1	https://creativecommons.org/licenses/by-nc/4.0/	ORG
dpc-4838	11	1	pirro federico	PERSON
dpc-4838	11	2	uoc dermatologia	PERSON
dpc-4838	11	3	fondazione policlinico universitario a. gemelli irccs	ORG
dpc-4838	11	4	8	CARDINAL
dpc-4838	11	5	rome	GPE
dpc-4838	11	6	italy	GPE
dpc-4838	12	1	2	CARDINAL
dpc-4838	13	1	2025;15(1):4838	CARDINAL
dpc-4838	13	2	italian	NORP
dpc-4838	13	3	1.8% to 4.8%	PERCENT
dpc-4838	13	4	1,2	CARDINAL
dpc-4838	13	5	over 100 million	CARDINAL
dpc-4838	13	6	3	CARDINAL
dpc-4838	14	1	4,5	CARDINAL
dpc-4838	14	2	6	CARDINAL
dpc-4838	15	1	il17	ORG
dpc-4838	15	2	il23	PRODUCT
dpc-4838	17	1	antiinterleukin	PERSON
dpc-4838	17	2	il17	ORG
dpc-4838	17	3	il23	PRODUCT
dpc-4838	17	4	9	CARDINAL
dpc-4838	17	5	anti-tnf	NORP
dpc-4838	17	6	adalimumab	PERSON
dpc-4838	18	1	6	CARDINAL
dpc-4838	19	1	secukinumab	PERSON
dpc-4838	19	2	interleukin-17a	CARDINAL
dpc-4838	19	3	first	ORDINAL
dpc-4838	19	4	anti-il17	NORP
dpc-4838	19	5	fda	ORG
dpc-4838	19	6	ema	ORG
dpc-4838	19	7	2015	DATE
dpc-4838	19	8	10	CARDINAL
dpc-4838	20	1	two	CARDINAL
dpc-4838	20	2	11	CARDINAL
dpc-4838	21	1	secukinumab	PERSON
dpc-4838	21	2	up to 1 year	DATE
dpc-4838	21	3	12	CARDINAL
dpc-4838	22	1	risankizumab	PERSON
dpc-4838	22	2	il23	ORG
dpc-4838	22	3	13	CARDINAL
dpc-4838	22	4	fda	ORG
dpc-4838	22	5	ema	ORG
dpc-4838	22	6	2019	DATE
dpc-4838	22	7	14	CARDINAL
dpc-4838	23	1	secukinumab	PERSON
dpc-4838	23	2	15	CARDINAL
dpc-4838	24	1	secukinumab	PERSON
dpc-4838	24	2	16,17	CARDINAL
dpc-4838	25	1	secukinumab	PERSON
dpc-4838	26	1	2021	CARDINAL
dpc-4838	27	1	risankizumab	PERSON
dpc-4838	27	2	secukinumab	PERSON
dpc-4838	28	1	risankizumab	ORG
dpc-4838	28	2	secukinumab	PERSON
dpc-4838	28	3	two	CARDINAL
dpc-4838	29	1	italy	GPE
dpc-4838	29	2	secukinumab	GPE
dpc-4838	29	3	between september 2020 to september 2022	DATE
dpc-4838	30	1	16	CARDINAL
dpc-4838	30	2	52	DATE
dpc-4838	30	3	78 weeks	DATE
dpc-4838	31	1	pasi90	ORG
dpc-4838	32	1	week 16 and 52	DATE
dpc-4838	33	1	141	CARDINAL
dpc-4838	33	2	74	DATE
dpc-4838	33	3	52.5%	PERCENT
dpc-4838	33	4	67	DATE
dpc-4838	33	5	47.5%	PERCENT
dpc-4838	34	1	secukinumab	PERSON
dpc-4838	34	2	weeks 16	DATE
dpc-4838	34	3	52	DATE
dpc-4838	34	4	79.7%	PERCENT
dpc-4838	34	5	64.2%	PERCENT
dpc-4838	34	6	0.041	CARDINAL
dpc-4838	34	7	98.6%	PERCENT
dpc-4838	34	8	83.6%	PERCENT
dpc-4838	34	9	0.003	CARDINAL
dpc-4838	35	1	risankizumab	PERSON
dpc-4838	35	2	week 52	DATE
dpc-4838	35	3	85.5%	PERCENT
dpc-4838	35	4	65.6%	PERCENT
dpc-4838	35	5	0.009	CARDINAL
dpc-4838	36	1	pasi90	NORP
dpc-4838	36	2	2	CARDINAL
dpc-4838	36	3	week 78	DATE
dpc-4838	37	1	pasi90	NORP
dpc-4838	37	2	5833.66	MONEY
dpc-4838	37	3	8394.78	MONEY
dpc-4838	37	4	8747.18	MONEY
dpc-4838	37	5	10746.53	MONEY
dpc-4838	37	6	52	CARDINAL
dpc-4838	37	7	11798.90	MONEY
dpc-4838	37	8	13598.73	MONEY
dpc-4838	37	9	15347.70	MONEY
dpc-4838	37	10	19568.31	MONEY
dpc-4838	38	1	risankizumab	PERSON
dpc-4838	40	1	2025;15(1):4838 3	CARDINAL
dpc-4838	40	2	two	CARDINAL
dpc-4838	40	3	18	CARDINAL
dpc-4838	41	1	secukinumab	PERSON
dpc-4838	41	2	19,20	CARDINAL
dpc-4838	42	1	risankizumab	ORG
dpc-4838	42	2	secukinumab	PERSON
dpc-4838	42	3	two	CARDINAL
dpc-4838	42	4	italy	GPE
dpc-4838	43	1	secukinumab	GPE
dpc-4838	43	2	between september 2020	DATE
dpc-4838	43	3	september 2022	DATE
dpc-4838	44	1	5	CARDINAL
dpc-4838	44	2	fondazione policlinico universitario a. gemelli irccs	ORG
dpc-4838	44	3	fondazione policlinico tor vergata	ORG
dpc-4838	44	4	policlinico umberto	PERSON
dpc-4838	45	1	sapienza	GPE
dpc-4838	45	2	università di roma	PERSON
dpc-4838	45	3	p.o. centro “a. fiorini	ORG
dpc-4838	45	4	terracina sapienza	GPE
dpc-4838	45	5	università di roma polo pontino	PERSON
dpc-4838	45	6	lazio	GPE
dpc-4838	45	7	italy	GPE
dpc-4838	46	1	18 years old	DATE
dpc-4838	48	1	il23	PRODUCT
dpc-4838	48	2	secukinumab	PERSON
dpc-4838	48	3	il17	ORG
dpc-4838	49	1	risankizumab	PERSON
dpc-4838	49	2	secukinumab	PERSON
dpc-4838	49	3	ema	ORG
dpc-4838	50	1	two	CARDINAL
dpc-4838	50	2	the first year	DATE
dpc-4838	50	3	300 mg	QUANTITY
dpc-4838	50	4	2100 mg	QUANTITY
dpc-4838	50	5	secukinumab	PERSON
dpc-4838	50	6	16 weeks	DATE
dpc-4838	50	7	one	CARDINAL
dpc-4838	50	8	2 75 mg	QUANTITY
dpc-4838	50	9	150 mg	QUANTITY
dpc-4838	50	10	every 12 weeks	DATE
dpc-4838	50	11	risankizumab	ORG
dpc-4838	50	12	one	CARDINAL
dpc-4838	50	13	2 150 mg	QUANTITY
dpc-4838	50	14	300 mg	QUANTITY
dpc-4838	50	15	every 4 weeks	DATE
dpc-4838	50	16	secukinumab	GPE
dpc-4838	51	1	secukinumab.	GPE
dpc-4838	54	1	21	CARDINAL
dpc-4838	54	2	16	CARDINAL
dpc-4838	54	3	52	DATE
dpc-4838	54	4	78 weeks	DATE
dpc-4838	55	1	aes	ORG
dpc-4838	55	2	aes	ORG
dpc-4838	56	1	helsinki	PERSON
dpc-4838	58	1	90%	PERCENT
dpc-4838	58	2	100%	PERCENT
dpc-4838	58	3	baseline to weeks 16	DATE
dpc-4838	58	4	52	DATE
dpc-4838	58	5	78	CARDINAL
dpc-4838	60	1	week 16 and 52	DATE
dpc-4838	61	1	week 78	DATE
dpc-4838	62	1	1162.79	MONEY
dpc-4838	62	2	75-mg	QUANTITY
dpc-4838	62	3	400.99	MONEY
dpc-4838	62	4	150-mg	QUANTITY
dpc-4838	63	1	16 and 52 weeks	DATE
dpc-4838	63	2	pasi90	NORP
dpc-4838	64	1	0.05	CARDINAL
dpc-4838	65	1	13.0	CARDINAL
dpc-4838	65	2	statacorp	ORG
dpc-4838	65	3	texas	GPE
dpc-4838	66	1	141	CARDINAL
dpc-4838	66	2	74	DATE
dpc-4838	66	3	52.5%	PERCENT
dpc-4838	66	4	67	DATE
dpc-4838	66	5	47.5%	PERCENT
dpc-4838	66	6	secukinumab	GPE
dpc-4838	67	1	51.2 ± 16.4	QUANTITY
dpc-4838	67	2	50.9 ±	CARDINAL
dpc-4838	67	3	secukinumab group	ORG
dpc-4838	68	1	77.0%	PERCENT
dpc-4838	68	2	risankizumab	ORG
dpc-4838	68	3	41.8%	PERCENT
dpc-4838	68	4	0.00005	CARDINAL
dpc-4838	68	5	1.3 ± 1.3	CARDINAL
dpc-4838	68	6	0.6 ± 0.89	MONEY
dpc-4838	68	7	0.001	CARDINAL
dpc-4838	69	1	two	CARDINAL
dpc-4838	69	2	17.0	CARDINAL
dpc-4838	69	3	17.2	CARDINAL
dpc-4838	69	4	secukinumab	PERSON
dpc-4838	70	1	1	CARDINAL
dpc-4838	71	1	weeks 16	DATE
dpc-4838	71	2	52	DATE
dpc-4838	71	3	78	CARDINAL
dpc-4838	71	4	secukinumab	GPE
dpc-4838	72	1	2 (	PERCENT
dpc-4838	72	2	2.9%	PERCENT
dpc-4838	72	3	weeks 17 and 19	DATE
dpc-4838	73	1	aes	ORG
dpc-4838	74	1	4	CARDINAL
dpc-4838	75	1	2025;15(1):4838	CARDINAL
dpc-4838	75	2	79.7%	PERCENT
dpc-4838	75	3	64.2%	PERCENT
dpc-4838	75	4	secukinumab	GPE
dpc-4838	75	5	pasi90	NORP
dpc-4838	75	6	week 16	DATE
dpc-4838	75	7	0.041	CARDINAL
dpc-4838	75	8	week 16	DATE
dpc-4838	75	9	2	CARDINAL
dpc-4838	76	1	week 52	DATE
dpc-4838	76	2	pasi 90	ORG
dpc-4838	76	3	98.6%	PERCENT
dpc-4838	76	4	83.6%	PERCENT
dpc-4838	76	5	secukinumab	PERSON
dpc-4838	76	6	0.003	CARDINAL
dpc-4838	77	1	risankizumab	PERSON
dpc-4838	77	2	week 52	DATE
dpc-4838	77	3	85.5%	PERCENT
dpc-4838	77	4	65.6%	PERCENT
dpc-4838	78	1	pasi90	NORP
dpc-4838	78	2	2	CARDINAL
dpc-4838	78	3	week 78	DATE
dpc-4838	78	4	95.16%	PERCENT
dpc-4838	78	5	82.26%	PERCENT
dpc-4838	78	6	89.83%	PERCENT
dpc-4838	78	7	72.88%	PERCENT
dpc-4838	79	1	2	CARDINAL
dpc-4838	79	2	1	CARDINAL
dpc-4838	80	1	secukinumab	PERSON
dpc-4838	80	2	pasi90	NORP
dpc-4838	80	3	weeks	DATE
dpc-4838	80	4	1	CARDINAL
dpc-4838	82	1	risankizumab secukinumab	PERSON
dpc-4838	82	2	74 67	DATE
dpc-4838	82	3	age (years	DATE
dpc-4838	82	4	±	CARDINAL
dpc-4838	82	5	51.2	CARDINAL
dpc-4838	82	6	14.3 0.862	CARDINAL
dpc-4838	82	7	55.4%	PERCENT
dpc-4838	82	8	67.2%	PERCENT
dpc-4838	82	9	0.137	CARDINAL
dpc-4838	82	10	77.8 ±	CARDINAL
dpc-4838	82	11	78.8 ±	QUANTITY
dpc-4838	82	12	15.7 0.400	CARDINAL
dpc-4838	82	13	years ±	DATE
dpc-4838	82	14	21.1 ±	MONEY
dpc-4838	82	15	77.0%	PERCENT
dpc-4838	82	16	41.8%	PERCENT
dpc-4838	82	17	0.00005a	CARDINAL
dpc-4838	82	18	±	CARDINAL
dpc-4838	82	19	1.3 ±	MONEY
dpc-4838	82	20	±	CARDINAL
dpc-4838	82	21	17.0 ±	MONEY
dpc-4838	83	1	2	CARDINAL
dpc-4838	83	2	weeks 16	DATE
dpc-4838	83	3	52	DATE
dpc-4838	83	4	78	CARDINAL
dpc-4838	84	1	pasi risankizumab secukinumab delta risankizumab	PERSON
dpc-4838	84	2	secukinumab p	ORG
dpc-4838	84	3	74 67	CARDINAL
dpc-4838	84	4	90 week	DATE
dpc-4838	84	5	16 79.7%	PERCENT
dpc-4838	84	6	64.2%	PERCENT
dpc-4838	84	7	15.6%	PERCENT
dpc-4838	84	8	0.041	CARDINAL
dpc-4838	84	9	100 week	DATE
dpc-4838	84	10	16 55.4%	PERCENT
dpc-4838	84	11	52.2%	PERCENT
dpc-4838	84	12	3.2%	PERCENT
dpc-4838	84	13	0.707	CARDINAL
dpc-4838	84	14	69 61	CARDINAL
dpc-4838	84	15	90 week	DATE
dpc-4838	84	16	98.6%	PERCENT
dpc-4838	84	17	83.6%	PERCENT
dpc-4838	84	18	14.9%	PERCENT
dpc-4838	84	19	0.003	CARDINAL
dpc-4838	84	20	100 week	DATE
dpc-4838	84	21	85.5%	PERCENT
dpc-4838	84	22	65.6%	PERCENT
dpc-4838	84	23	19.9%	PERCENT
dpc-4838	84	24	0.009	CARDINAL
dpc-4838	84	25	62	CARDINAL
dpc-4838	84	26	90 week	DATE
dpc-4838	84	27	78 95.16%	PERCENT
dpc-4838	84	28	89.83%	PERCENT
dpc-4838	84	29	5.3%	PERCENT
dpc-4838	84	30	100	CARDINAL
dpc-4838	84	31	78 82.26%	PERCENT
dpc-4838	84	32	72.88%	PERCENT
dpc-4838	84	33	9.4%	PERCENT
dpc-4838	84	34	0.218	CARDINAL
dpc-4838	85	1	16	CARDINAL
dpc-4838	85	2	52	DATE
dpc-4838	85	3	3	CARDINAL
dpc-4838	86	1	week 16	DATE
dpc-4838	86	2	pasi90	ORG
dpc-4838	86	3	5833.66	MONEY
dpc-4838	86	4	risankizumab	ORG
dpc-4838	86	5	8747.18	MONEY
dpc-4838	86	6	secukinumab	GPE
dpc-4838	86	7	8394.78	MONEY
dpc-4838	86	8	risankizumab	ORG
dpc-4838	86	9	10746.53	MONEY
dpc-4838	86	10	secukinumab	GPE
dpc-4838	87	1	risankizumab	PERSON
dpc-4838	87	2	secukinumab	GPE
dpc-4838	87	3	week 52	DATE
dpc-4838	87	4	pasi90	NORP
dpc-4838	87	5	€11798.90 and €13598.73	MONEY
dpc-4838	87	6	15347.70	MONEY
dpc-4838	87	7	19568.31	MONEY
dpc-4838	88	1	2	CARDINAL
dpc-4838	88	2	italy	GPE
dpc-4838	88	3	secukinumab	GPE
dpc-4838	89	1	78 weeks	DATE
dpc-4838	90	1	secukinumab	PERSON
dpc-4838	92	1	2025;15(1):4838 5	CARDINAL
dpc-4838	92	2	1	CARDINAL
dpc-4838	93	1	weeks 16	DATE
dpc-4838	93	2	52	DATE
dpc-4838	93	3	78	CARDINAL
dpc-4838	94	1	3	CARDINAL
dpc-4838	95	1	pasi90	NORP
dpc-4838	95	2	weeks 16 and 52	DATE
dpc-4838	96	1	secukinumabb	GPE
dpc-4838	96	2	delta risankizumab	ORG
dpc-4838	96	3	secukinumab pasi	PERSON
dpc-4838	96	4	90 week	DATE
dpc-4838	96	5	16 € 5833.66 €	MONEY
dpc-4838	96	6	8747.18	MONEY
dpc-4838	96	7	2913.52	CARDINAL
dpc-4838	96	8	100	CARDINAL
dpc-4838	96	9	16 € 8394.78 €	MONEY
dpc-4838	96	10	10746.53	MONEY
dpc-4838	96	11	2351.76	CARDINAL
dpc-4838	96	12	90 week	DATE
dpc-4838	96	13	€ 11798.90 € 15347.70	MONEY
dpc-4838	96	14	3548.80	CARDINAL
dpc-4838	96	15	100	CARDINAL
dpc-4838	96	16	19568.31	MONEY
dpc-4838	96	17	5969.58	CARDINAL
dpc-4838	96	18	1162.79	MONEY
dpc-4838	96	19	75-mg	QUANTITY
dpc-4838	96	20	400.99	MONEY
dpc-4838	96	21	150-mg	QUANTITY
dpc-4838	98	1	risankizumab pasi90	PERSON
dpc-4838	98	2	week 16	DATE
dpc-4838	98	3	79.7%	PERCENT
dpc-4838	98	4	55.4%	PERCENT
dpc-4838	98	5	week 52	DATE
dpc-4838	98	6	98.6%	PERCENT
dpc-4838	98	7	85.5%	PERCENT
dpc-4838	98	8	week 52	DATE
dpc-4838	98	9	13	CARDINAL
dpc-4838	100	1	pasi90	NORP
dpc-4838	100	2	64.2%	PERCENT
dpc-4838	100	3	52.2%	PERCENT
dpc-4838	100	4	week 16	DATE
dpc-4838	100	5	83.6%	PERCENT
dpc-4838	100	6	65.6%	PERCENT
dpc-4838	100	7	week 52	DATE
dpc-4838	100	8	11	CARDINAL
dpc-4838	101	1	secukinumab	PERSON
dpc-4838	101	2	22	CARDINAL
dpc-4838	102	1	secukinumab	PERSON
dpc-4838	102	2	anti-il23	ORG
dpc-4838	102	3	anti-il17	NORP
dpc-4838	102	4	26,27	CARDINAL
dpc-4838	102	5	16,17	CARDINAL
dpc-4838	103	1	pasi90	NORP
dpc-4838	104	1	98.6%	PERCENT
dpc-4838	104	2	pasi90	NORP
dpc-4838	104	3	83.6%	PERCENT
dpc-4838	105	1	risankizumab	PERSON
dpc-4838	105	2	secukinumab	PERSON
dpc-4838	105	3	il23	PRODUCT
dpc-4838	106	1	6	CARDINAL
dpc-4838	107	1	2025;15(1):4838	CARDINAL
dpc-4838	107	2	daily	DATE
dpc-4838	108	1	japanese	NORP
dpc-4838	108	2	adalimumab	PERSON
dpc-4838	108	3	ustekinumab	PERSON
dpc-4838	108	4	secukinumab	GPE
dpc-4838	109	1	risankizumab	ORG
dpc-4838	109	2	32	CARDINAL
dpc-4838	111	1	two	CARDINAL
dpc-4838	112	1	secukinumab	PERSON
dpc-4838	112	2	2015	DATE
dpc-4838	112	3	150 mg	QUANTITY
dpc-4838	112	4	400.99	MONEY
dpc-4838	112	5	1162.79	MONEY
dpc-4838	112	6	italian	NORP
dpc-4838	113	1	secukinumab	PERSON
dpc-4838	114	1	risankizumab	PERSON
dpc-4838	114	2	annual	DATE
dpc-4838	114	3	il17	ORG
dpc-4838	114	4	il23	PRODUCT
dpc-4838	114	5	33	CARDINAL
dpc-4838	115	1	annual	DATE
dpc-4838	116	1	anti-tnf	NORP
dpc-4838	116	2	28	CARDINAL
dpc-4838	117	1	two	CARDINAL
dpc-4838	117	2	77.0%	PERCENT
dpc-4838	117	3	41.8%	PERCENT
dpc-4838	117	4	29,30	CARDINAL
dpc-4838	118	1	pasi90	ORG
dpc-4838	118	2	22,31	CARDINAL
dpc-4838	119	1	only 16 weeks	DATE
dpc-4838	119	2	anti-il23	PERSON
dpc-4838	119	3	anti-il17	NORP
dpc-4838	119	4	15	CARDINAL
dpc-4838	120	1	risankizumab	PERSON
dpc-4838	121	1	gisondi et al	PERSON
dpc-4838	122	1	18	CARDINAL
dpc-4838	122	2	up to 2 years	DATE
dpc-4838	124	1	2	CARDINAL
dpc-4838	124	2	weeks 16 and 52	DATE
dpc-4838	126	1	2025;15(1):4838	CARDINAL
dpc-4838	126	2	gianfredi v	ORG
dpc-4838	126	3	casu g	PERSON
dpc-4838	126	4	kacerik e	PERSON
dpc-4838	126	5	signorelli c.	PERSON
dpc-4838	126	6	italy	GPE
dpc-4838	129	1	2022;93(6):e2022332 3	CARDINAL
dpc-4838	129	2	parisi r	PERSON
dpc-4838	129	3	iskandar iyk	ORG
dpc-4838	129	4	augustin m	PERSON
dpc-4838	129	5	griffiths cem	PERSON
dpc-4838	129	6	ashcroft dm	PERSON
dpc-4838	132	1	2020	DATE
dpc-4838	132	2	4	CARDINAL
dpc-4838	133	1	armstrong aw	PERSON
dpc-4838	135	1	1945-1960 5	DATE
dpc-4838	136	1	alwan w	PERSON
dpc-4838	136	2	nestle	ORG
dpc-4838	138	1	clin exp	PERSON
dpc-4838	139	1	2015;33(5	CARDINAL
dpc-4838	139	2	kim j	PERSON
dpc-4838	139	3	krueger jg	PERSON
dpc-4838	140	1	17	CARDINAL
dpc-4838	141	1	annu rev med	ORG
dpc-4838	142	1	2017 jan 14;68:255-269 7	DATE
dpc-4838	142	2	di cesare	PERSON
dpc-4838	142	3	di meglio p	PERSON
dpc-4838	142	4	nestle	ORG
dpc-4838	145	1	2009	DATE
dpc-4838	145	2	jun;129(6):1339-50 8	EVENT
dpc-4838	146	1	rendon	GPE
dpc-4838	146	2	k. psoriasis pathogenesis	PERSON
dpc-4838	147	1	j mol sci	PERSON
dpc-4838	147	2	2019	DATE
dpc-4838	148	1	tokuyama m	PERSON
dpc-4838	149	1	j mol sci	PERSON
dpc-4838	149	2	2020	DATE
dpc-4838	149	3	oct 11;21(20):7488 10	DATE
dpc-4838	150	1	sanford m	PERSON
dpc-4838	150	2	k. secukinumab	PERSON
dpc-4838	150	3	first	ORDINAL
dpc-4838	152	1	2015;75(3):329	CARDINAL
dpc-4838	153	1	langley rg	PERSON
dpc-4838	153	2	lebwohl m	PERSON
dpc-4838	153	3	secukinumab	PERSON
dpc-4838	153	4	two	CARDINAL
dpc-4838	153	5	3	CARDINAL
dpc-4838	156	1	reich k	PERSON
dpc-4838	156	2	tsai tf	PERSON
dpc-4838	156	3	kingo k	PERSON
dpc-4838	156	4	secukinumab	PERSON
dpc-4838	156	5	up to 1 year	DATE
dpc-4838	157	1	j am	PERSON
dpc-4838	158	1	2017 jan;76((1)):60–69.e9 13	DATE
dpc-4838	159	1	gordon kb	PERSON
dpc-4838	159	2	lebwohl m	PERSON
dpc-4838	159	3	augustin m	PERSON
dpc-4838	159	4	poulin y	PERSON
dpc-4838	159	5	papp ka	PERSON
dpc-4838	159	6	sofen h	ORG
dpc-4838	159	7	puig l	ORG
dpc-4838	159	8	foley p	PERSON
dpc-4838	159	9	geng z	PERSON
dpc-4838	159	10	gu y	PERSON
dpc-4838	159	11	valdes jm	PERSON
dpc-4838	159	12	thompson ehz	PERSON
dpc-4838	159	13	bachelez h.	ORG
dpc-4838	159	14	two	CARDINAL
dpc-4838	159	15	3	CARDINAL
dpc-4838	160	1	lancet	ORG
dpc-4838	161	1	2018	DATE
dpc-4838	161	2	25;392(10148):650-661 14	DATE
dpc-4838	161	3	mckeage k	PERSON
dpc-4838	161	4	duggan s. risankizumab	PERSON
dpc-4838	161	5	first	ORDINAL
dpc-4838	163	1	2019;79(8):893	CARDINAL
dpc-4838	164	1	warren	PERSON
dpc-4838	164	2	poulin y	PERSON
dpc-4838	164	3	kelly m	PERSON
dpc-4838	164	4	wu t	PERSON
dpc-4838	164	5	geng z	PERSON
dpc-4838	164	6	paul c.	PERSON
dpc-4838	164	7	secukinumab	PERSON
dpc-4838	166	1	2021	CARDINAL
dpc-4838	166	2	59 16	CARDINAL
dpc-4838	167	1	mastorino l	FAC
dpc-4838	167	2	secukinumab	GPE
dpc-4838	167	3	ixekizumab	PERSON
dpc-4838	167	4	guselkumab	PERSON
dpc-4838	167	5	risankizumab	PERSON
dpc-4838	167	6	tildrakizumab	PERSON
dpc-4838	168	1	november 5	DATE
dpc-4838	168	2	2023 17	DATE
dpc-4838	169	1	t, puig l	GPE
dpc-4838	169	2	il)-17	ORG
dpc-4838	170	1	j clin	PERSON
dpc-4838	171	1	2022;23(6):891-904 18	CARDINAL
dpc-4838	172	1	gisondi p	PERSON
dpc-4838	172	2	loconsole f	PERSON
dpc-4838	172	3	raimondo p	PERSON
dpc-4838	172	4	r.	NORP
dpc-4838	172	5	di risankizumab e	PERSON
dpc-4838	172	6	secukinumab nel trattamento	PERSON
dpc-4838	172	7	della psoriasi	PERSON
dpc-4838	172	8	da moderata	PERSON
dpc-4838	173	1	reg	CARDINAL
dpc-4838	173	2	health technol	ORG
dpc-4838	174	1	2021;8:120	CARDINAL
dpc-4838	175	1	anti-tnf	NORP
dpc-4838	178	1	one	CARDINAL
dpc-4838	180	1	daily	DATE
dpc-4838	182	1	52 weeks	DATE
dpc-4838	182	2	the first year	DATE
dpc-4838	182	3	two	CARDINAL
dpc-4838	182	4	week 78	DATE
dpc-4838	184	1	european	NORP
dpc-4838	184	2	extra-european	NORP
dpc-4838	185	1	one	CARDINAL
dpc-4838	185	2	italy	GPE
dpc-4838	187	1	pasi90	NORP
dpc-4838	187	2	italy	GPE
dpc-4838	189	1	1	CARDINAL
dpc-4838	190	1	cantini f.	PERSON
dpc-4838	190	2	italy	GPE
dpc-4838	191	1	curr	PERSON
dpc-4838	192	1	2018;20(7):43	CARDINAL
dpc-4838	193	1	10.1007	CARDINAL
dpc-4838	193	2	018-0753-1	DATE
dpc-4838	194	1	29846817	DATE
dpc-4838	195	1	8	CARDINAL
dpc-4838	196	1	2025;15(1):4838	CARDINAL
dpc-4838	198	1	2022;12(2):561-575 29	CARDINAL
dpc-4838	199	1	papp ka	PERSON
dpc-4838	199	2	gordon kb	PERSON
dpc-4838	199	3	langley rg	PERSON
dpc-4838	200	1	320	CARDINAL
dpc-4838	201	1	garcía	GPE
dpc-4838	201	2	ferrandiz c	ORG
dpc-4838	202	1	j dermatolog	PERSON
dpc-4838	203	1	2016;27(3):203-209 31	CARDINAL
dpc-4838	204	1	gkalpakiotis s	PERSON
dpc-4838	204	2	cetkovska	PERSON
dpc-4838	204	3	arenberger p	PERSON
dpc-4838	204	4	dolezal t	GPE
dpc-4838	204	5	arenbergerova	GPE
dpc-4838	204	6	velackova	GPE
dpc-4838	204	7	kojanova	PERSON
dpc-4838	205	1	risankizumab	PERSON
dpc-4838	205	2	the czech republic	GPE
dpc-4838	207	1	2021	CARDINAL
dpc-4838	207	2	5:1–11 32	DATE
dpc-4838	208	1	saeki h	ORG
dpc-4838	208	2	ishii k	PERSON
dpc-4838	208	3	bensimon ag	ORG
dpc-4838	208	4	yang h	PERSON
dpc-4838	208	5	kawaguchi i.	PERSON
dpc-4838	208	6	japan	GPE
dpc-4838	209	1	j dermatolog	PERSON
dpc-4838	210	1	2022;33(1):229-239 33	DATE
dpc-4838	211	1	norden	GPE
dpc-4838	211	2	moon jy	PERSON
dpc-4838	211	3	javadi ss	PERSON
dpc-4838	211	4	wu jj	PERSON
dpc-4838	213	1	2022;36(8):1171-1177 34	CARDINAL
dpc-4838	214	1	de simone c	PERSON
dpc-4838	214	2	caldarola	ORG
dpc-4838	215	1	anti-tnf	NORP
dpc-4838	217	1	2016;29(5):372	CARDINAL
dpc-4838	218	1	mourad	ORG
dpc-4838	218	2	straube s	ORG
dpc-4838	218	3	armijo-olivo s	ORG
dpc-4838	218	4	gniadecki r.	PERSON
dpc-4838	220	1	2019;181(3	CARDINAL
dpc-4838	220	2	450	CARDINAL
dpc-4838	222	1	wu jj	PERSON
dpc-4838	222	2	jia x	PERSON
dpc-4838	222	3	zhao y	PERSON
dpc-4838	223	1	j dermatolog	PERSON
dpc-4838	224	1	2021;32(7):693-700 20	CARDINAL
dpc-4838	225	1	skowron f. cost	PERSON
dpc-4838	225	2	france	GPE
dpc-4838	225	3	germany	GPE
dpc-4838	226	1	curr med res opin	ORG
dpc-4838	227	1	2023;39(6):833-842 21	DATE
dpc-4838	228	1	fredriksson t	ORG
dpc-4838	229	1	dermatologica	PERSON
dpc-4838	230	1	1978;157(4):238-44 22	DATE
dpc-4838	231	1	caldarola	ORG
dpc-4838	231	2	zangrilli	PERSON
dpc-4838	231	3	risankizumab	PERSON
dpc-4838	231	4	1 year	DATE
dpc-4838	233	1	2022	CARDINAL
dpc-4838	233	2	35(6):e15489 23	DATE
dpc-4838	234	1	brunasso amg	PERSON
dpc-4838	234	2	amoruso	PERSON
dpc-4838	234	3	risankizumab	PERSON
dpc-4838	234	4	daily	DATE
dpc-4838	236	1	2023;11(6):1769 24	DATE
dpc-4838	237	1	dastoli s	PERSON
dpc-4838	238	1	240 weeks	DATE
dpc-4838	238	2	italy	GPE
dpc-4838	239	1	j dermatolog	PERSON
dpc-4838	240	1	2023;34(1):2200868 25	DATE
dpc-4838	241	1	von kiedrowski	PERSON
dpc-4838	241	2	secukinumab	PERSON
dpc-4838	243	1	2020;34(2):310-318 26	CARDINAL
dpc-4838	243	2	narcisi	PERSON
dpc-4838	243	3	valenti m	PERSON
dpc-4838	243	4	anti-il17	NORP
dpc-4838	243	5	anti-il23	NORP
dpc-4838	245	1	2022;35(2):e15228	CARDINAL
dpc-4838	249	1	2023	CARDINAL
dpc-4838	249	2	15(3):9692 28	DATE
dpc-4838	250	1	crowley jj	PERSON
dpc-4838	250	2	langley rg	PERSON
dpc-4838	250	3	gordon kb	PERSON
dpc-4838	250	4	secukinumab	PERSON